07:33 AM EDT, 03/24/2025 (MT Newswires) -- Entrada Therapeutics ( TRDA ) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.

The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.

Entrada said it is on course to begin the trial in Q3.

Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.